Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiling in myeloid cells of chronic myeloid leukemia patients

ABSTRACT: Gene expression profiling in myeloid cells of chronic myeloid leukemia patients

PROVIDER: PRJNA681902 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13177308_1.fastq.gz	Fastqsanger.gz
	SRR13177308_2.fastq.gz	Fastqsanger.gz
	SRR13177309_1.fastq.gz	Fastqsanger.gz
	SRR13177309_2.fastq.gz	Fastqsanger.gz
	SRR13177310.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 57

Similar Datasets

Comparison of microRNA Expression Profile in Patients with Chronic Myeloid Leukemia Treated by Allogeneic Hematopoietic Stem Cell Transplantation and Chronic Myeloid Leukemia patients treated with imatinib mesylate.

Project description:Expression profile of 14 Chronic Myeloid Leukemia Philadelphia chromossome negative patients after allo haematopoietc stem cell transplantation and Chronic Myeloid Leukemia treated with imatinib mesylate. We tested 754 microRNAs by reverse transcription quantitative polymerase chain reaction (RT-qPCR) array for each patient.

2021-01-12 | GSE164549 | GEO

Gene expression profiling in myeloid cells of chronic myeloid leukemia patients

Project description:To clarify whether myeloid cells in chroninc myeloid leukemia (CML) harbor any signs of altered characteristics, we performed transcriptome analyses of type 1 conventional dendritic cells (cDC1s), basophils, monocytes, and neutrophils isolated from peripheral blood of CML patients and healthy donors. Taken together with the flow cytometric analyses of these cells and bone marrow progenitors, our results indicated that anti-tumor immunity is impaired in CML patients by BCR-ABL via both disrupting cDC1 development and promoting myeloid cell-mediated immune suppression.

2021-09-15 | GSE162462 | GEO

Transcription profiling of blood from human patients with chronic myeloid leukemia harboring different bcr-abl transcript variants

Project description:Identification of differentially expressed genes in the blood of chronic phase patients with chronic myeloid leukemia (CML) harboring different bcr-abl transcript variants. All leukemic samples were collected prior to therapy at the time point of the initial diagnosis of CML.

2008-12-31 | E-MEXP-862 | biostudies-arrayexpress

Exosomal miRNA expression profiling in patients with imatinib-resistant chronic myeloid leukemia

Project description:Exosomal miRNA expression profiling in patients with imatinib-resistant chronic myeloid leukemia

| PRJNA1231083 | ENA

Protein coding gene expression profile of dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib

Project description:Dasatinib has demonstrated efficacy in patients with chronic-phase chronic myeloid leukemia (CML) who had resistance or intolerance to imatinib. However, some patients also develop resistance or intolerance to dasatinib. To identify potential molecular pathways involved in primary resistance to dasatinib in CML, we analyzed gene expression profiles of mononuclear cells of 7 imatinib-resistant patients, collected before and after 1-year dasatinib treatment. Large-scale gene expression was measured with Agilent microarrays covering protein-coding genes and long (>200 nt) noncoding RNAs (lncRNAs). Sets of genes and lncRNAs significantly differentially expressed (>1.5 fold-change; q value ?10%) were identified. Ingenuity Pathway Analysis pointed to a number of functions, canonical pathways and gene networks that were significantly enriched with differentially expressed genes. In addition to protein-coding genes, lncRNAs have been recently implicated in pathways leading to tumorigenesis. Our data point to new possible regulatory elements involved in dasatinib resistance in CML. Dasatinib pre-treatment and 1-yr post-treatment samples from 3 responders (R) or 4 non-responders (NR) chronic myeloid leukemia (CML) patients were investigated. We analyzed expression of Pre-treatment R vs. Pre-treatment NR; Pre-treatment R vs. Post-treatment NR; Pre-treatment NR vs. Post-treatment NR.

2013-07-31 | E-GEOD-33224 | biostudies-arrayexpress

Discovery of the targets of the immune response to chronic lymphocytic and myeloid leukemia

Project description:This SuperSeries is composed of the following subset Series: GSE11564: Discovery of the targets of the immune response to chronic lymphocytic leukemia in 2 patients using protein microarrays GSE11565: Discovery of the targets of the immune response to chronic myeloid leukemia in 3 patients using protein microarrays Keywords: SuperSeries Refer to individual Series

2008-05-31 | E-GEOD-11566 | biostudies-arrayexpress

Noncoding RNA expression profile of dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib

Project description:Dasatinib has demonstrated efficacy in patients with chronic-phase chronic myeloid leukemia (CML) who had resistance or intolerance to imatinib. However, some patients also develop resistance or intolerance to dasatinib. To identify potential molecular pathways involved in primary resistance to dasatinib in CML, we analyzed gene expression profiles of mononuclear cells of 7 imatinib-resistant patients, collected before and after 1-year dasatinib treatment. Large-scale gene expression was measured with Agilent microarrays covering protein-coding genes and long (>200 nt) noncoding RNAs (lncRNAs). Sets of genes and lncRNAs significantly differentially expressed (>1.5 fold-change; q value ≤10%) were identified. Ingenuity Pathway Analysis pointed to a number of functions, canonical pathways and gene networks that were significantly enriched with differentially expressed genes. In addition to protein-coding genes, lncRNAs have been recently implicated in pathways leading to tumorigenesis. Our data point to new possible regulatory elements involved in dasatinib resistance in CML. Dasatinib pre-treatment and 1-yr post-treatment samples from 3 responders (R) or 4 non-responders (NR) chronic myeloid leukemia (CML) patients were investigated. We analyzed expression of Pre-treatment R vs. Pre-treatment NR; Pre-treatment R vs. Post-treatment NR; Pre-treatment NR vs. Post-treatment NR.

2013-07-31 | E-GEOD-33288 | biostudies-arrayexpress

Gene expression signatures of dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib

Project description:Dasatinib has demonstrated efficacy in patients with chronic-phase chronic myeloid leukemia (CML) who had resistance or intolerance to imatinib. However, some patients also develop resistance or intolerance to dasatinib. To identify potential molecular pathways involved in primary resistance to dasatinib in CML, we analyzed gene expression profiles of mononuclear cells of 7 imatinib-resistant patients, collected before and after 1-year dasatinib treatment. Large-scale gene expression was measured with Agilent microarrays covering protein-coding genes and long (>200 nt) noncoding RNAs (lncRNAs). Sets of genes and lncRNAs significantly differentially expressed (>1.5 fold-change; q value ≤10%) were identified. Ingenuity Pathway Analysis pointed to a number of functions, canonical pathways and gene networks that were significantly enriched with differentially expressed genes. In addition to protein-coding genes, lncRNAs have been recently implicated in pathways leading to tumorigenesis. Our data point to new possible regulatory elements involved in dasatinib resistance in CML. This SuperSeries is composed of the SubSeries listed below. Refer to individual Series.

2013-07-31 | E-GEOD-33290 | biostudies-arrayexpress

Characterization of miRNomes in acute and chronic myeloid leukemia cells

Project description:An in-depth analysis of miRNomes in 3 human myeloid leukemia cell lines was carried out to comprehensively identify miRNAs that distinguish acute and chronic myeloid leukemias and relate to myeloid cell differentiation. Characterization the miRNomes in 3 myeloid leukemia cell lines.

2014-07-03 | E-GEOD-48059 | biostudies-arrayexpress

Multiomic profiling of adult acute myeloid leukemia patients

Project description:Multiomic profiling of adult acute myeloid leukemia patients

| PRJNA1143594 | ENA